-
Nov 26, 2024 | 
healio.com | Savannah Demko |Heather Biele
You've successfully added Liver/Biliary Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
October 30, 2024 2 min watch VIDEO: T-DXd shows promise for patients with HER2-positive with brain metastases Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Breast Cancer. Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
VIDEO: Longer follow-up may increase benefits of ribociclib in some patients with breast cancerSara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial. The data, presented at ESMO Congress, showed the benefit seen after patients with hormone receptor-positive, HER2-negative breast cancer were off ribociclib (Kisqali, Novartis), Tolaney told Healio in a video interview.
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
VIDEO: Pembrolizumab ‘should be standard of care’ for stage II or III triple-negative breast cancerSara M.
-
Oct 15, 2024 | 
healio.com | Holly Liptak |Savannah Demko
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Alokkumar Jha, PhD, MSc, BE, spoke with Healio about key presentations from the American Neurological Association annual meeting.
-
Oct 2, 2024 | 
healio.com | Savannah Demko |Nancy Lin |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In a video interview,Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.
-
Oct 2, 2024 | 
healio.com | Savannah Demko |Nancy Lin |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.
-
Oct 2, 2024 | 
healio.com | Savannah Demko |Nancy Lin |Mindy Valcarcel
Source: Healio Interviews Disclosures: Lin reports receiving institutional research support, consulting honoraria, travel and/or royalties from AstraZeneca, Artera Inc., Blueprint Medicines, Daichii-Sankyo, Eisai, Genentech, Janssen, Olema Pharmaceuticals, Pfizer, Merck, Seagen, Stemline/Menarini, Up To Date and Zion Pharmaceuticals.
-
Dec 18, 2023 | 
healio.com | Savannah Demko |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video,Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia A gene therapy, which she presented in a session at ASH Annual Meeting and Exposition.
-
Dec 18, 2023 | 
healio.com | Savannah Demko |Mindy Valcarcel |Lindsey Roeker
You've successfully added Hematology Oncology: Leukemia to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well-tolerated in relapsed or refractory CLL.
